Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/275
DC FieldValueLanguage
dc.contributor.authorMano, Antonio-
dc.contributor.authorFalcão, Amílcar-
dc.contributor.authorGodinho, I.-
dc.contributor.authorSantos, J.-
dc.contributor.authorLeitão, F.-
dc.contributor.authorOliveira, C.-
dc.contributor.authorCaramona, M.-
dc.date.accessioned2008-06-17T15:01:57Z-
dc.date.available2008-06-17T15:01:57Z-
dc.date.issued2005-05-
dc.identifier.citationGynecologic Oncology 97:2 (2005) 529-534en_US
dc.identifier.issn0090-8258-
dc.identifier.urihttp://hdl.handle.net/10316/275-
dc.descriptionPrémio atribuído pelo International Research Promotion Council a Amílcar C. Falcão: Eminent Scientist of the Year 2006. Europe-
dc.description.abstractAbstract Objective The aim of the present study was to investigate the usefulness of the CA-125 area under the curve (AUC) as a new kinetic parameter for predicting overall survival in patients with ovarian cancer. In addition, the relationship of CA-125 AUC with other prognostic factors of ovarian cancer was evaluated. Methods Ninety-two patients that underwent primary line chemotherapy within 4 months after submission to cytoreductive surgery were included. For each patient, CA-125 AUC was calculated and a statistical analysis was conducted to compare CA-125 AUC behavior among patients according to several covariates. Results The mean age at diagnostic time was found to be 55.5 (16.1–82.4) years with a mean survival of 39.2 (3.5–100.1; SE = 2.6) months. Across FIGO stage I, II, III, and IV patients had a mean CA-125 AUC of 18.2, 24.6, 147.8, and 574.6 IU/ml*days, respectively (P < 0.05). At the evaluation date, living patients had a mean CA-125 AUC of 40.1 in contrast to 234.1 IU/ml*days (P < 0.05) for deceased ones. Patients with a complete response to primary chemotherapy had a mean CA-125 AUC of 48.8, while patients with a partial response had a mean of 251.7 IU/ml*days, and patients with no response or disease progression had a mean of 316.5 IU/ml*days (P < 0.05). The best CA-125 AUC performance is in predicting patient complete response to chemotherapy with a cut-off of 100 IU/ml*days and an accuracy of 82%. Conclusions Despite CA-125 AUC high correlation with the FIGO stage, residual disease, and patient final outcome, the main interest of CA-125 AUC calculation is to evaluate the treatment efficacy and to foresee a full chemotherapy response. Further studies should be carried out before extrapolating these results to other data sets.en_US
dc.format.mimetypeaplication/PDFen
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsopenAccesseng
dc.subjectneoplasias do ovarioen_US
dc.subjectprognosticoen_US
dc.subjectmarcadores tumoraisen_US
dc.subjectfarmacocinéticaen_US
dc.subjectCA 125en_US
dc.titleCA-125 AUC as a new prognostic factor for patients with ovarian canceren_US
dc.typearticleen_US
dc.identifier.doi10.1016/j.ygyno.2005.01.040-
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.languageiso639-1en-
crisitem.author.deptFaculty of Pharmacy-
crisitem.author.deptFaculty of Sciences and Technology-
crisitem.author.deptFaculty of Pharmacy-
crisitem.author.parentdeptUniversity of Coimbra-
crisitem.author.researchunitCEMMPRE - Centre for Mechanical Engineering, Materials and Processes-
crisitem.author.orcid0000-0002-3854-6549-
crisitem.author.orcid0000-0003-4936-9434-
Appears in Collections:FFUC- Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
CA-125.pdf239.33 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

20
checked on Aug 2, 2022

Page view(s) 50

566
checked on Sep 29, 2022

Download(s) 50

399
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.